The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the clinical and economic outcomes of tabelecleucel for the treatment of EBV+PTLD. This report summarizes the findings and highlights the key policy recommendations discussed at the New England Comparative Effectiveness Public Advisory Council’s public meeting on November 14, 2024. The detailed report is available at https://icer.org/wp-content/uploads/2024/12/ICER_EBV-PTLD_Final-Evidence-Report_For-Publication_121624.pdf.
